menu
    • menu
    [{"orgOrder":0,"company":"ViGeneron","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"vgAAV.GL","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"ViGeneron","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ViGeneron \/ Daiichi Sankyo","highestDevelopmentStatusID":"4","companyTruncated":"ViGeneron \/ Daiichi Sankyo"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"CXCL-12","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TME Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"TME Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Eyevensys","sponsor":"Korea Investment Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"EYS809","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Eyevensys","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eyevensys \/ Korea Investment Partners","highestDevelopmentStatusID":"4","companyTruncated":"Eyevensys \/ Korea Investment Partners"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            TME Pharma

                            Germany arrow
                            APGA Annual Conference
                            Not Confirmed

                            TME Pharma

                            Germany arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emapticap pegol

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TME Pharma Announces Plan to Externalize and Monetize NOX-E36

                            Details : NOX-E36 (emapticap pegol) is an injectable PEGylated L-stereoisomer RNA aptamer that inhibits chemokine CCL2 and is in preclinical studies for early glaucoma treatment.

                            Product Name : NOX-E36

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            July 22, 2024

                            Lead Product(s) : Emapticap pegol

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ViGeneron

                            Germany arrow
                            APGA Annual Conference
                            Not Confirmed

                            ViGeneron

                            Germany arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : vgAAV.GL

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : Daiichi Sankyo

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            ViGeneron Announces Follow-On Collaboration with Daiichi Sankyo to Develop a Novel Gene Therapy for Prevalent ...

                            Details : The companies agree a follow-on collaboration to evaluate ViGeneron’s adeno-associated virus vectors (vgAAVs) for delivering Daiichi Sankyo’s novel therapeutic protein to treat prevalent eye diseases.

                            Product Name : vgAAV.GL

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 26, 2022

                            Lead Product(s) : vgAAV.GL

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : Daiichi Sankyo

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Eyevensys

                            Germany arrow
                            APGA Annual Conference
                            Not Confirmed

                            Eyevensys

                            Germany arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EYS809

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : Korea Investment Partners

                            Deal Size : $12.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Eyevensys Raises $12M in a Series B Plus Funding Round

                            Details : The financing will support Eyevensys’ accelerated development of its EYS809 program for the treatment of wet age-related macular degeneration (AMD), a chronic eye disorder that causes blurred vision or a blind spot in the eye.

                            Product Name : EYS809

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 08, 2021

                            Lead Product(s) : EYS809

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : Korea Investment Partners

                            Deal Size : $12.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth